Natera, Inc. (NASDAQ:NTRA) CEO Sells $634,774.08 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,816 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $93.13, for a total value of $634,774.08. Following the completion of the transaction, the chief executive officer now directly owns 227,710 shares of the company’s stock, valued at approximately $21,206,632.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
• On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $964,178.17.
• On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The stock was sold at an average price of $68.16, for a total transaction of $133,457.28.

Natera Stock Performance

NASDAQ:NTRA traded up $0.01 during mid-day trading on Wednesday, hitting $90.33. 694,054 shares of the company’s stock traded hands, compared to its average volume of 1,470,209. The firm has a 50 day moving average of $85.39 and a two-hundred day moving average of $65.41. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $98.82. The firm has a market capitalization of $10.91 billion, a price-to-earnings ratio of -23.83 and a beta of 1.37. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. On average, equities analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Crossmark Global Holdings Inc. grew its stake in shares of Natera by 2.2% during the fourth quarter. Crossmark Global Holdings Inc. now owns 7,267 shares of the medical research company’s stock worth $456,000 after purchasing an additional 155 shares during the period. Fifth Third Bancorp grew its stake in shares of Natera by 3.0% during the fourth quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after purchasing an additional 179 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Natera by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after purchasing an additional 230 shares during the period. Royal Bank of Canada grew its stake in shares of Natera by 0.3% during the third quarter. Royal Bank of Canada now owns 83,843 shares of the medical research company’s stock worth $3,710,000 after purchasing an additional 245 shares during the period. Finally, Xponance Inc. grew its stake in shares of Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after purchasing an additional 261 shares during the period. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent research reports. Stephens reiterated an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. BTIG Research upped their price target on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a report on Friday, December 29th. Craig Hallum started coverage on shares of Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target for the company. Piper Sandler boosted their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, The Goldman Sachs Group boosted their price objective on shares of Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.